ERBB2 and cancer: In the entire cohort, the majority of the patients were of age >50 years (70%), early‐stage cancer—stages I and II (80%), infiltrating ductal carcinoma (78.5%), ER+ (72.9%), PR+ (65.6%), and HER2− (77.6%).